CorMedix (CRMD) Cash & Equivalents (2010 - 2025)

CorMedix has disclosed Cash & Equivalents across 16 years of filings, most recently posting $144.8 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $144.8 million, up 256.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $144.8 million (up 256.29% YoY), and the FY2025 annual result was $144.8 million, up 256.29% from the prior year.
• Cash & Equivalents came in at $144.8 million for Q4 2025 at CorMedix, up from $48.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $159.3 million in Q2 2025 to a low of $19.7 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $43.4 million (2022), against an average of $55.1 million.
• Across the five-year window, Cash & Equivalents surged 599.08% in 2021 and tumbled 70.38% in 2022, its largest moves.
• CorMedix's Cash & Equivalents stood at $53.3 million in 2021, then dropped by 19.07% to $43.1 million in 2022, then advanced by 1.15% to $43.6 million in 2023, then retreated by 6.85% to $40.7 million in 2024, then surged by 256.29% to $144.8 million in 2025.
• The last three Cash & Equivalents figures came in at $144.8 million (Q4 2025), $48.5 million (Q3 2025), and $159.3 million (Q2 2025), per Business Quant data.